These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 31338384)

  • 1. Prevalence of Anti-Adeno-Associated Virus Immune Responses in International Cohorts of Healthy Donors.
    Kruzik A; Fetahagic D; Hartlieb B; Dorn S; Koppensteiner H; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Mol Ther Methods Clin Dev; 2019 Sep; 14():126-133. PubMed ID: 31338384
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neutralizing antibodies against adeno-associated virus examined prospectively in pediatric patients with hemophilia.
    Li C; Narkbunnam N; Samulski RJ; Asokan A; Hu G; Jacobson LJ; Manco-Johnson MJ; Monahan PE;
    Gene Ther; 2012 Mar; 19(3):288-94. PubMed ID: 21697954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Detection of Biologically Relevant Low-Titer Neutralizing Antibodies Against Adeno-Associated Virus Require Sensitive
    Kruzik A; Koppensteiner H; Fetahagic D; Hartlieb B; Dorn S; Romeder-Finger S; Coulibaly S; Weber A; Hoellriegl W; Horling FM; Scheiflinger F; Reipert BM; de la Rosa M
    Hum Gene Ther Methods; 2019 Apr; 30(2):35-43. PubMed ID: 30734588
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence and long-term monitoring of humoral immunity against adeno-associated virus in Duchenne Muscular Dystrophy patients.
    Leborgne C; Latournerie V; Boutin S; Desgue D; Quéré A; Pignot E; Collaud F; Charles S; Simon Sola M; Masat E; Jouen F; Boyer O; Masurier C; Mingozzi F; Veron P
    Cell Immunol; 2019 Aug; 342():103780. PubMed ID: 29571923
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevalence and Relevance of Pre-Existing Anti-Adeno-Associated Virus Immunity in the Context of Gene Therapy for Crigler-Najjar Syndrome.
    Aronson SJ; Veron P; Collaud F; Hubert A; Delahais V; Honnet G; de Knegt RJ; Junge N; Baumann U; Di Giorgio A; D'Antiga L; Ginocchio VM; Brunetti-Pierri N; Labrune P; Beuers U; Bosma PJ; Mingozzi F
    Hum Gene Ther; 2019 Oct; 30(10):1297-1305. PubMed ID: 31502485
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Pre-Existing Neutralizing Antibodies Against Adeno-Associated Virus Serotypes 1, 2, 5, 6, 8, and 9 in Sera of Different Pig Strains.
    Dai Y; Kavita U; Lampen MH; Gielen S; Banks G; Levesque P; Kozhich A; Pillutla R; Zhang Y; Jawa V; Adam L
    Hum Gene Ther; 2022 Apr; 33(7-8):451-459. PubMed ID: 34913759
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prevalence of serum IgG and neutralizing factors against adeno-associated virus (AAV) types 1, 2, 5, 6, 8, and 9 in the healthy population: implications for gene therapy using AAV vectors.
    Boutin S; Monteilhet V; Veron P; Leborgne C; Benveniste O; Montus MF; Masurier C
    Hum Gene Ther; 2010 Jun; 21(6):704-12. PubMed ID: 20095819
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neutralizing antibodies against AAV2, AAV5 and AAV8 in healthy and HIV-1-infected subjects in China: implications for gene therapy using AAV vectors.
    Liu Q; Huang W; Zhang H; Wang Y; Zhao J; Song A; Xie H; Zhao C; Gao D; Wang Y
    Gene Ther; 2014 Aug; 21(8):732-8. PubMed ID: 24849042
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Application of polyploid adeno-associated virus vectors for transduction enhancement and neutralizing antibody evasion.
    Chai Z; Sun J; Rigsbee KM; Wang M; Samulski RJ; Li C
    J Control Release; 2017 Sep; 262():348-356. PubMed ID: 28789965
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful liver transduction by re-administration of different adeno-associated virus vector serotypes in mice.
    Baatartsogt N; Kashiwakura Y; Hiramoto T; Hayakawa M; Kamoshita N; Ohmori T
    J Gene Med; 2023 Aug; 25(8):e3505. PubMed ID: 36972408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Global Seroprevalence of Pre-existing Immunity Against AAV5 and Other AAV Serotypes in People with Hemophilia A.
    Klamroth R; Hayes G; Andreeva T; Gregg K; Suzuki T; Mitha IH; Hardesty B; Shima M; Pollock T; Slev P; Oldenburg J; Ozelo MC; Stieltjes N; Castet SM; Mahlangu J; Peyvandi F; Kazmi R; Schved JF; Leavitt AD; Callaghan M; Pan-Petesch B; Quon DV; Andrews J; Trinh A; Li M; Wong WY
    Hum Gene Ther; 2022 Apr; 33(7-8):432-441. PubMed ID: 35156839
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pre-existing antibodies to candidate gene therapy vectors (adeno-associated vector serotypes) in domestic cats.
    Li P; Boenzli E; Hofmann-Lehmann R; Helfer-Hungerbuehler AK
    PLoS One; 2019; 14(3):e0212811. PubMed ID: 30897117
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MSD-based assays facilitate a rapid and quantitative serostatus profiling for the presence of anti-AAV antibodies.
    Haar J; Blazevic D; Strobel B; Kreuz S; Michelfelder S
    Mol Ther Methods Clin Dev; 2022 Jun; 25():360-369. PubMed ID: 35573045
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adenovirus-associated antibodies in UK cohort of hemophilia patients: A seroprevalence study of the presence of adenovirus-associated virus vector-serotypes AAV5 and AAV8 neutralizing activity and antibodies in patients with hemophilia A.
    Stanford S; Pink R; Creagh D; Clark A; Lowe G; Curry N; Pasi J; Perry D; Fong S; Hayes G; Chandrakumaran K; Rangarajan S
    Res Pract Thromb Haemost; 2019 Apr; 3(2):261-267. PubMed ID: 31011710
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of robust immune responses against human immunodeficiency virus is supported by the inherent tropism of adeno-associated virus type 5 for dendritic cells.
    Xin KQ; Mizukami H; Urabe M; Toda Y; Shinoda K; Yoshida A; Oomura K; Kojima Y; Ichino M; Klinman D; Ozawa K; Okuda K
    J Virol; 2006 Dec; 80(24):11899-910. PubMed ID: 17005662
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Seroprevalence of Adeno-Associated Virus Neutralizing Antibodies in Males with Duchenne Muscular Dystrophy.
    Verma S; Nwosu SN; Razdan R; Upadhyayula SR; Phan HC; Koroma AA; Leguizamo I; Correa NS; Kuipa M; Lee D; Vanderford TH; Gardner MR
    Hum Gene Ther; 2023 May; 34(9-10):430-438. PubMed ID: 36324212
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enhanced liver gene transfer and evasion of preexisting humoral immunity with exosome-enveloped AAV vectors.
    Meliani A; Boisgerault F; Fitzpatrick Z; Marmier S; Leborgne C; Collaud F; Simon Sola M; Charles S; Ronzitti G; Vignaud A; van Wittenberghe L; Marolleau B; Jouen F; Tan S; Boyer O; Christophe O; Brisson AR; Maguire CA; Mingozzi F
    Blood Adv; 2017 Oct; 1(23):2019-2031. PubMed ID: 29296848
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The prevalence of neutralizing antibodies against adeno-associated virus capsids is reduced in young Japanese individuals.
    Mimuro J; Mizukami H; Shima M; Matsushita T; Taki M; Muto S; Higasa S; Sakai M; Ohmori T; Madoiwa S; Ozawa K; Sakata Y
    J Med Virol; 2014 Nov; 86(11):1990-7. PubMed ID: 24136735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Adeno-associated virus serotype 1 (AAV1)- and AAV5-antibody complex structures reveal evolutionary commonalities in parvovirus antigenic reactivity.
    Tseng YS; Gurda BL; Chipman P; McKenna R; Afione S; Chiorini JA; Muzyczka N; Olson NH; Baker TS; Kleinschmidt J; Agbandje-McKenna M
    J Virol; 2015 Feb; 89(3):1794-808. PubMed ID: 25410874
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Multiplexing AAV Serotype-Specific Neutralizing Antibodies in Preclinical Animal Models and Humans.
    Kuoch H; Krotova K; Graham ML; Brantly ML; Aslanidi G
    Biomedicines; 2023 Feb; 11(2):. PubMed ID: 36831059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.